NCT05707390View on ClinicalTrials.gov

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

September 13, 2023

Study Completion Date

September 13, 2023

Conditions
Hepatic Impairment
Interventions
DRUG

Mezigdomide

Specified dose on specified days

Trial Locations (3)

32809

Orlando Clinical Research Center OCRC, Orlando

33014

PANAX, Miami Lakes

78215

The Texas Liver Institute, San Antonio

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05707390 - A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment | Biotech Hunter | Biotech Hunter